ARNA Genomics is an innovative biotechnological company, launched on the basis of the
scientific and research laboratory and a team of like-minded people, engaged in development and research of early detection methods of oncological diseases with the purpose of launch of diagnostic tests for early cancer detection on the global market.
Our mission is to increase the life expectancy and significantly reduce human mortality by means of global market launch of most recent, unique in efficiency methods of screening (screening study with the purpose of detection and prevention of disease development in population), diagnostics (correct diagnosing) and monitoring of treatment process of oncological diseases.
ARNA Genomics company has discovered a technology which allows to develop tests for different types (nosologies) of cancer. Besides, the company has also developed a unique concept of blockchain based ecosystem, which will be used as an instrument to support R&D and implementation of biotechnologies worldwide.
We have completed R&D for the first product based on our technology – breast cancer test.
Colon cancer test is currently in R&D stage. Besides, we are currently developing a blockchain platform solution – ARNA Panacea, which will soon allow to change the world by making launch of new biotech solutions against cancer much easier and faster.
ARNA Panacea is platform which allows not processing of clinical trials data and also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients).
The platform’s initial purpose is to gain, store and analyze information on all the methods of cancer detection and treatment from all over the world. This would allow researchers getting more accurate and precise knowledge on the subject on one hand, and on the other — will provide trustable and accessible proof to all market participants on research results conducted throughout their lifecycle.
2013
2014
2015
2016
2017
2018
2019
Verified 0%
Attention. There is a risk that unverified members are not actually members of the team
Verified 0%
Attention. There is a risk that unverified members are not actually members of the team
ARNA Genomics is developing a blockchain technology called ARNA Panacea. That blockchain features a data storage system and ecosystem catered towards the world of medical research. Researchers are incentivized to share data with the platform, while regulators can view data as evidence that a particular trial or test was successful.
ARNA Genomics, prior to creating this blockchain platform, has been heavily involved with creating early detection tests for cancer – including breast cancer tests. ARNA Panacea is designed to feature research from its early cancer detection tests – as well as the tests created by medical research companies worldwide.
This offer is based solely on information provided by the offeror and other publicly available sources.
The token sale or exchange event is completely independent of ICOholder. ICOholder is not involved in any way, including technical support or promotion.
We list token sales from entities with which we have no relationship to help users track overall activity within the token sector. This information is not intended as advice, and you should seek professional or specialist guidance or conduct your own due diligence before making any decisions based on our content.
Any terms and conditions regarding token acquisition are solely between contributors and the token issuer. ICOholder is not the seller of these tokens.
ICOholder is not legally responsible for any representations made by third parties about any token sale. Any claims for breach of contract must be directed against the listed token issuing entity.
If you have concerns about the nature, legality, or propriety of a token sale or the involved individuals, please contact info@icoholder.com with detailed information.